Slide-Seq for Spatially Mapping Gene Expression. Metabolic Syndrome Exacerbates Group 2 Pulmonary Hypertension, and NAD Metabolism Is Influenced by Tissue Origin.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Identification and functional analysis of NADFrontiers in genetics · 2026
   Article
2. Spatiotemporal multi-omics: exploring molecular landscapes in aging and regenerative medicine.Military Medical Research · 2024
   Review
3. Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence.Signal transduction and targeted therapy · 2021
   Review

Corrections and comments

• Comment on
  Slide-seq: A scalable technology for measuring genome-wide expression at high spatial resolution.2019
• Comment on
  NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling.2019
• Comment on
  Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.2019

Authors and funding

5 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as